目的 觀察補肺活血膠囊治療輕中型新型冠狀病毒肺炎的臨床療效。方法 選取2022年12月-2023年4月河南省中醫(yī)院收治的160例輕中型新型冠狀病毒肺炎患者,按照隨機數(shù)字表法將納入病例隨機分為對照組(80例)和治療組(80例)。對照組患者給予常規(guī)藥物治療。治療組患者在對照組治療基礎上口服補肺活血膠囊,4粒/次,3次/d。兩組患者連續(xù)治療2周。觀察兩組的臨床療效、胸部CT影像學改善情況、核酸轉陰時間、癥狀持續(xù)時間、住院天數(shù),比較兩組治療前后炎癥指標、凝血功能指標、肺炎嚴重程度(PSI)評分、CURB-65評分、臨床肺部感染(CPIS)評分的變化情況。結果 治療后,治療組的總有效率為83.75%,顯著高于對照組的43.75%(P<0.05)。治療組胸部CT改善情況與對照組比較差異無統(tǒng)計學意義。與對照組比較,治療組患者核酸轉陰時間、癥狀持續(xù)時間、住院天數(shù)均顯著降低(P<0.05)。治療后,兩組患者C反應蛋白(CRP)水平均降低,而白細胞(WBC)、中性粒細胞比例(NEUT%)、淋巴細胞百分比(LYMPH%)水平均升高(P<0.05);治療后,治療組CRP水平低于對照組,WBC、NEUT%、LYMPH%水平高于對照組(P<0.05)。治療后,兩組凝血酶原時間(PT)、活化部分凝血活酶時間(APTT)、D-二聚體均下降,而凝血酶時間(TT)水平則增加(P<0.05);治療后,治療組關于凝血功能指標的調控效果更顯著(P<0.05)。治療后,兩組PSI評分、CURB-65評分及CPIS評分較治療前均顯著下降(P<0.05);治療后,治療組PSI評分、CURB-65評分及CPIS評分低于對照組(P<0.05)。結論 補肺活血膠囊治療新型冠狀病毒肺炎臨床療效良好,可以抑制炎癥反應,糾正血液高凝狀態(tài),從而縮短核酸轉陰時間和住院天數(shù),緩解患者臨床癥狀,且安全性較高。

Objective To observe the efficacy of Bufei Huoxue Capsules in treatment of mild and moderate novel coronavirus pneumonia. Methods A total of 160 patients with mild and moderate novel coronavirus pneumonia admitted to Henan Provincial Hospital of Traditional Chinese Medicine from December 2022 to April 2023 were selected and randomly divided into control group (80 cases) and treatment group (80 cases) according to random number table method. Patients in the control group were given conventional drug treatment. Patients in the treatment group were po administered with Bufei Huoxue Capsules on the basis of control group, 4 capsules/time, 3 times daily. Both groups were treated continuously for 2 weeks. The clinical efficacy, chest CT imaging improvement, nucleic acid negative time, symptom duration and hospital stay of two groups were observed, and the changes of inflammation index, coagulation function index, pneumonia severity (PSI) score, CURB-65 score and clinical pulmonary infection (CPIS) score before and after treatment were compared between the two groups. Results After treatment, the total effective rate of treatment group was 83.75%, which was significantly higher than that of control group (43.75%, P < 0.05). There was no significant difference in the improvement of chest CT between treatment group and control group. Compared with the control group, the time of nucleic acid turning negative, symptom duration and hospitalization days in treatment group were significantly reduced (P < 0.05). After treatment, C-reactive protein (CRP) levels were decreased in both groups, but leukocyte (WBC), neutrophil percentage (NEUT%) and lymphocyte percentage (LYMPH%) levels were increased in both groups (P < 0.05). After treatment, CRP levels in treatment group were lower than those in control group, WBC, NEUT% and LYMPH% levels were higher than those in control group (P < 0.05). After treatment, the prothrombin time (PT), activated partial thromboplastin time (APTT) and D-dimer were all decreased, but the thrombin time (TT) level was increased in both groups (P < 0.05). After treatment, the regulation effect of coagulation function index in treatment group was increased significantly (P < 0.05). After treatment, PSI score, CURB-65 score and CPIS score in both groups were significantly decreased compared with before treatment (P < 0.05). After treatment, the PSI score, CURB-65 score and CPIS score of treatment group were lower than those of control group (P < 0.05). Conclusion Bufei Huoxue Capsules has good clinical efficacy in treatment of novel coronavirus pneumonia, and can inhibit inflammation, correct blood hypercoagulability, shorten the negative nucleic acid time and hospitalization days, which can relieve clinical symptoms of patients with high safety.

R974

河南省中醫(yī)藥科學研究專項課題（2023ZY3008）